相关实验视频
Updated: Jun 5, 2025

Chinese Herbal Retention Enema for the Treatment of Ulcerative Colitis
Published on: May 16, 2025
口服奇托桑-环德克斯"外核心"纳米颗粒共载莱因和酸治疗性结肠炎治疗
Wenbiao Nie1, Wenzhen Zhong1, Lin Qian2
1State Key Laboratory of Southwestern Chinese Medicine Resources, Pharmacy School, Chengdu University of Traditional Chinese Medicine, Chengdu 611130, China.
这项研究开发了新型纳米颗粒,用于联合输送莱因和酸治疗性结肠炎 (UC). 纳米系统有效降低了炎症和氧化应激,显示出协同治疗效应.
科学领域:
- 生物材料科学 生物材料科学
- 纳米技术纳米技术
- 胃肠病学 胃肠病学
背景情况:
- 性结肠炎 (UC) 治疗面临的挑战是口服同时输送的食品衍生化合物,如莱因 (RH) 和酸 (CGA).
- RH和CGA具有抗炎和抗氧化特性,但它们不同的物理化学特性阻碍了有效的联合交付.
- 现有的方法与胃肠道的不稳定性和对这些化合物的不充分的结肠向性斗争.
研究的目的:
- 开发一种新的纳米系统,用于对莱 (RH) 和酸 (CGA) 的联合封装和有针对性的输送.
- 克服口服联合分娩的挑战,包括不同的水友性/疏水性,不稳定性和结肠向性.
- 研究RH和CGA在性结肠炎 (UC) 治疗中的协同抗炎和抗氧化作用.
主要方法:
- 使用循环德克斯基聚合物和叶酸-阿曼塔丁聚合物开发外核心纳米粒子 (CP@CGA-FA/TA@RH NPs).
- 在核心中共同封装莱恩 (RH),以向巨细胞,并在基托外中同时封装基酸 (CGA),以释放微环境敏感物质.
- 在体外对纳米颗粒对TLR4/MyD88/NF-κB抗炎途径和Nrf2/HO-1抗氧化途径的影响的评估.
主要成果:
- CP@CGA-FA/TA@RH NPs证明了TLR4/MyD88/NF-κB通路的有效抑制和Nrf2/HO-1通路的激活.
- Q值分析证实了莱 (RH) 和酸 (CGA) 之间显著的协同效应.
- 开发的纳米系统成功地解决了共同交付方面的挑战,提高了稳定性和定位.
结论:
- 这项研究介绍了第一个纳米系统,它结合了两种来自食物的成分,用于整合UC治疗.
- 开发的纳米颗粒为增强雷恩 (RH) 和酸 (CGA) 治疗性结肠炎的治疗疗效提供了一个有希望的策略.
- 通过纳米技术提供RH和CGA的协同行动和有针对性的交付,为管理UC提供了一种新的方法.
更多相关视频
08:53Investigating the Alleviating Effects of Bacillus cereus Administration on Colitis through Gut Microbiota Modulation
Published on: July 27, 2022
08:58Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis
Published on: January 5, 2017
相关概念视频
Drugs for Treatment of Ulcerative Colitis in IBD
Peptic Ulcer Disease IV: Management
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
Drugs for Treatment of Constipation-Predominant IBS